[Form 4] Genelux Corporation Insider Trading Activity

Rhea-AI Filing Summary

Yong Yu, SVP Clinical Development of Genelux Corporation (GNLX), reported equity awards and option grants dated 08/27/2025. The filing shows an acquisition of 101,480 restricted stock units (RSUs) under the 2022 Equity Incentive Plan and a stock option to buy 134,520 shares at an exercise price of $3.64 expiring 08/26/2035.

Following the RSU grant and other holdings, Mr. Yu beneficially owns 150,036 shares, which includes 916 shares from the Employee Stock Purchase Plan. The RSUs vest 25% after one year then quarterly over the remaining period; the option vests 25% after one year then monthly over three years.

Positive

• Significant equity awards (101,480 RSUs and option for 134,520 shares) indicate management retention and alignment with shareholders
• Clear vesting schedules (25% after one year then periodic vesting) promote multi-year retention
• Participation in ESPP: 916 shares held under the Employee Stock Purchase Plan

Negative

• Potential dilution when 101,480 RSUs settle and 134,520 options are exercised
• Option exercise price $3.64 may be below future market prices, increasing dilution risk if in‑the‑money

Insights

Financial Analyst

TL;DR: Routine compensation grants align executive incentives with shareholders but will increase share count when vested or exercised.

The Form 4 documents time‑based RSUs (101,480 units) and a large option grant (134,520 shares at $3.64) for an officer. Such grants are standard retention and incentive tools; the vesting schedules (initial 25% cliff then periodic vesting) suggest multi-year retention intent. Materiality depends on company share count (not provided). Investors should note potential dilution when RSUs settle and options are exercised, and the long 2035 option expiry leaves significant optionality.

Corporate Governance Expert

TL;DR: Disclosure is standard and timely; vesting terms indicate alignment but create future ownership changes.

The filing is properly executed and signed, with clear grant descriptions and vesting schedules. Time‑based vesting aligns the SVP with long‑term performance without immediate sales. The inclusion of 916 ESPP shares shows participation in employee plans. No departures, sales, or other governance events are reported. Impact is procedural rather than immediately material.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Yong

(Last) (First) (Middle)

C/O GENELUX CORPORATION

2625 TOWNSGATE ROAD, SUITE 230

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical Development

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		A(1)		101,480	A	$0	150,036(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.64	08/27/2025		A		134,520		(3)	08/26/2035	Common stock	134,520	$0	134,520	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.

2. Includes 916 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan.

3. The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

	/s/ Yong Yu	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did GNLX insider Yong Yu acquire on 08/27/2025?

Yong Yu was granted 101,480 RSUs and a stock option for 134,520 shares (exercise price $3.64, expiration 08/26/2035).

How many GNLX shares does Yong Yu beneficially own after the reported transactions?

The Form 4 reports 150,036 shares beneficially owned following the reported transactions, including 916 ESPP shares.

What are the vesting terms for the RSUs and options?

Both awards vest 25% on the first anniversary of the grant; RSUs then vest in 12 equal quarterly installments, options vest with the remaining 36 monthly installments.

When do the option and RSU transactions occur per the filing?

The transaction date for both the RSU grant and the option grant is 08/27/2025.

Does the filing indicate any sale or disposition of shares by Yong Yu?

No. The Form 4 reports acquisitions (RSUs and an option) and shows total beneficial ownership; there are no disposals reported.